EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Acute and 6-month vascular effects of a multi-component nutritional supplement: a randomized controlled trial

Charles Piercy, Jenny Harris, Kenza Sackho, Paola Campagnolo, Diogo Barardo, Ben Creagh-Brown, Christian Heiss

European Heart Journal Open · 2026-11-03 · 6 (6)

DOI: 10.1093/ehjopen/oeag157 ↗
AbstractBibliografische Angaben

Abstract

Abstract Aims To evaluate 6-month effects of a multi-ingredient nutritional powder formulation targeting complementary pathways relevant to vascular ageing on endothelial function and other vascular ageing markers in apparently healthy adults. Methods and results The effects of a supplement to target ageing mechanisms on vascular function study was a double-blind, randomized, controlled trial. Participants received a multi-ingredient nutritional powder formulation comprising vitamins/minerals, amino acids, and plant-derived bioactives, or control for 6 months. Vascular assessments were performed at baseline and after 6 months (with an acute post-dose assessment). The primary outcome was change in brachial artery flow-mediated dilation (FMD). Secondary outcomes included pulse wave velocity (PWV), peripheral and central blood pressure, augmentation index, lipid profile, and estimated 10-year cardiovascular risk (SCORE2/SCORE2-OP). Sixty-one participants (baseline SCORE2/SCORE2-OP 3.6 ± 2.9%) were randomized (33 actives; 28 controls); 43 completed both visits (24 vs. 19). Compared with control, the supplement improved endothelial function (ΔΔFMD at 6 months +2.9% [95% CI 2.1–3.8]) and reduced arterial stiffness (ΔΔPWV −1.18 m/s [95% CI −2.00 to −0.36]). Peripheral systolic blood pressure (SBP) decreased (ΔΔSBP −6.1 mmHg [95% CI −10.9 to −1.3]). Lipids were unchanged. Estimated 10-year cardiovascular risk decreased (ΔΔSCORE2/SCORE2-OP −0.45% [95% CI −0.86 to −0.03]). Conclusion Daily intake of a multi-ingredient nutritional powder formulation was associated with sustained improvements in endothelial function, arterial stiffness, and systolic blood pressure, with a modest reduction in estimated 10-year cardiovascular risk primarily attributable to lower systolic blood pressure rather than lipid change. Registration clinicaltrials.gov NCT06145087.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →